).
A small number of primary or metastatic breast cancer are oestrogen receptor negative (ER(-)) and progesterone receptor positive (PgR(+)) by conventional radioligand binding assays. In our series of 1,211 breast tumours 5.78% had this phenotype. In normal target cells the synthesis of progesterone receptor is under oestrogen control. In this context, the existence of ER(-) PgR(+) breast tumours represents an anomaly.
Several explanations can be put forward: technical deficiency, occupation of nuclear receptor sites by endogenous hormones or hormone therapy, existence of abnormal oestrogen receptors deficient in their hormone binding domain, or genuine ER(-) PgR(+) tumours.
The use of monoclonal anti ER and PgR antibodies (immunoassay in cytosolic and nuclear extracts, immunocytochemistry) has allowed to define several subgroups among these ER(-) PgR(+) tumours.
We Protein determinations Protein assays were carried out using the bis-cinchoninic acid reagent (BCA protein assay, Pierce).
Results
The overall results together with the clinical characteristics of the patients are listed in Table I . Our series of 15 ER(-) PgR(+) tumours can be stratified into three categories.
Patient numbers 1 and 2 received hormone therapy (contraceptive pills). In this situation, ER binding sites are partially or totally occupied, and hormone receptor complexes are less extractable by hypotonic buffers in cytosol. This results in an absence of binding sites by radioligand. However, some immunoassayable ER is found in tumour cytosol and nuclear extract. Elevated concentrations of PgR are observed in both tumours whatever the methods used.
Ten tumours (no. 3 to 12) displayed the same apparent phenotype, although none of these patients had received hormonal therapy. In all cases, immunoreactive ER is found in the nuclear fraction and in cytosol, except for tumour no. 5 in which the receptor is only present in nuclear extract.
ER was also observed in histologic sections, except for tumours no. 9 to 12. Breast cancer heterogeneity is a common feature of these tumours, and might explain that observation since PgR was present by Elisa techniques and immunocytochemistry in the same portions of the tumours.
This series of tumours may correspond to non-binding forms of ER, displaying a relatively low concentration of immunoreactive receptor in cytosol (16.1 ± 17.7 fmoles mg-' protein), the major part of it being in the nuclear fraction (64.2 ± 27.3% of total cellular ER). These tumours have elevated concentrations of PgR by binding and Elisa techniques, and are also positive by immunocytochemistry with high scores. The immumocytochemical assay of PgR in the tumour number 13 was also negative using different monoclonal antibodies. This result may be ascribed to the presence of a non-progesterone-receptor binding protein, perhaps the GCDFP-24 cyst protein described by Pearlman (1977) .
Tumours no. 14 and 15 exhibited a particular phenotype: the oestradiol receptor was absent in the cytosol and nuclear fractions by both steorid and immunoassay on histological slides. The progesterone receptor was evidenced by all available methods. These tumours are to be considered as 'true' ER negative, PgR positive tumours. 
Discussion
The 15 tumours of that study were taken from our library of 1,211 breast cancer, among which 70 (5.78%) are ER negative-PgR positive by steroid binding assays. This phenotype has been found to occur in 3% of 1,095 primary breast cancers by Kiang and Kollander (1987) and in approximatively 6% in another study by Sarrif and Durant (1981) . tumours, because they offer the alternative of antigenic recognition of the receptors, and are not hampered by the presence of endogenous hormones. They also allow a morphologic study of ER and PgR in breast tumours sections. Ten tumours of our series (no. 3 to 12) have immunoreactive ER, without oestrogen binding capacity in the cytosol. The progesterone receptor is present at relatively high concentrations by binding assay (range: 80-1,645 fmoles mg-' cytosol protein, mean concentration 366.4 fmoles mg-' cytosol protein). Since PgR was measured in parallel on the same cytosol preparation, it is improbable that the negative ER results are due to a technical failure, and intra and interassay standards of ER and PgR (calf uterine powder prepared and kept in liquid nitrogen) were also included in each experiment to validate the assays.
Similar results were obtained on 9/9 tumours by Kiang et al., and 7/8 tumours were found positive for ER by ICC. Our proportion of negative tumours by ICC is higher (4/10). The marked heterogeneity of breast cancer is probably the main explanation for this discrepancy. Adjacent sections for PgR immunocytochemistry were all found positive for those tumours, and positive control slides for ER and PgR were also included in the experiments.
No hormone therapy was given to those ten patients, 6/10 were menopaused, and one patient was in the follicular phase (7th day). Precise hormonal status was not available for three other patients.
A defective oestradiol receptor, with an altered steroid binding domain could be suspected to be present in these ten tumours. A similar conclusion has been drawn by Berkenstam et al. (1989) from their work on the hormonal regulation of ER mRNA in T47DcO and MCF-7 breast cancer cells. These authors showed that, in T47Dco cells, ER was absent by steroid binding assay and present at low concentration by Elisa assay, and that neither down regulation of ER mRNA by oestradiol, nor up regulation of PgR mRNA was observed, as it is seen in oestrogen responsive MCF-7 cells.
Finally, the most intriguing tumours are number 14 and 15. They are devoid of ER and express a functionally (at the binding level) and immunoreactive PgR. This is probably a very rare situation (2/15 = 13% of ER(-) PgR(+) in our series, or 0.17% of our overall series).
Two recent works put some insight on the molecular basis of these rare ER negative PgR positive tumours. Fuqua et al. (1991) have described a variant of ER devoid of exon 5 of the hormone binding domain, but able to stimulate PgR expression in three ER(-) PgR(+) breast tumours. Another situation was encountered in a T47D cell line with normal ER and an anomaly of one of the four copies of PgR gene present in these cells (Savouret et al., 1991) . It will thus be of interest to search for anomalies in the promoter region of the PgR gene in tumours expressing a true ER(-) PgR( +) phenotype.
